Ainsley Health

#8. Seema Alexander, CEO of Disruptive AI: From AI-Curious to AI-Powered Leadership

Featuring: Seema Alexander Hosted by: James Chhetree This episode of Ainsley Health features Seema Alexander, CEO of Disruptive AI, AI business futurist, keynote speaker, and host of The AI CEO Podcast. Hosted by James Chhetree, the conversation explores what it really takes for leaders, founders, and healthcare organizations to move beyond AI curiosity and into practical AI adoption. Seema brings a business-first lens to the AI conversation, helping executives understand that AI is not just another software tool. It is a fundamental shift in how organizations operate, compete, and create value. The discussion breaks down why the next era of AI will be defined less by hype and more by fluency, workflow redesign, and leadership readiness. Together, James and Seema explore several key themes: AI Fluency vs. AI Awareness: Why knowing what the tools do is no longer enough, and why leaders need to understand AI well enough to rethink how their organizations actually work. Rewiring the Business: How companies can move from scattered experiments to real operational transformation by redesigning workflows around AI, agents, and automation. The CEO’s Role in AI Adoption: Why AI strategy cannot live only with the technical team, and why executive alignment, governance, and change management are critical to adoption. Healthcare’s Next Transformation: How AI may reshape healthcare operations, patient engagement, administrative workflows, and the way organizations think about scale. Human-Centered AI: Why the best AI implementations should make teams more effective, not replace the judgment, trust, and relationships that matter most. Seema also shares her perspective on the broader AI business landscape, including why many organizations are still in the education phase, what separates serious adopters from passive observers, and how leaders can prepare their teams for the next wave of AI-enabled work. For founders, operators, healthcare executives, and anyone trying to understand where AI is actually going, this episode offers a practical look at how to lead through the shift from AI as a buzzword to AI as a business operating system. Please note that the content here is for informational purposes only; it should not be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security, and is not directed at any investors

#7. Demetri Giannikopoulos, Chief Innovation Officer at Rad AI: Rehumanizing Radiology Through AI Governance

Featuring: Demetri GiannikopoulosHosted by: Jay Gopal & James Chhetree This episode of Ainsley Health dives into the evolution of radiology as the vanguard of medical technology with Demetri Giannikopoulos, Chief Innovation Officer at Rad AI. Hosted by James Chhetree, the conversation explores how radiology moved from physical X-ray film to digital imaging decades before the rest of healthcare, and how that early adoption has paved the way for the modern generative AI era. Demetri brings over 20 years of experience, witnessing the transition from telephone-based dictation to the sophisticated AI synthesis used today. With Rad AI now utilized by 40% of US health systems and 9 out of 10 of the largest radiology practices, Demetri explains why the current shift is less about the technology itself and more about solving the "staccato" workflows that have burdened clinicians for years. As an industry expert who recently testified before the U.S. Senate on the "Less Hype, More Help" initiative, Demetri provides a comprehensive look at the ethical and practical deployment of AI: * Clinical Integration over Technology: Why moving from the pilot phase to full-scale implementation requires viewing AI as a governance consideration rather than just a software installation. * The Family Test: How reducing cognitive load through automated impression synthesis allows radiologists to return home less anxious, effectively "humanizing" the tech-heavy diagnostic process. * The Digital Front Door: The business and clinical case for Rad AI Continuity, which ensures incidental findings (incidentalomas) in the ER don't fall through the cracks, enabling a "stage shift" to catch diseases like lung cancer earlier. * The Future of the "Doctor's Doctor": A prediction on how AI will automate nearly 50% of routine tasks, allowing radiologists to move out of isolated workstations and back into the center of the diagnostic conversation. Demetri also shares personal insights into his own journey navigating the healthcare system as a patient, reinforcing the need for AI to remove the administrative friction of insurance and prior authorizations. For founders, he offers a masterclass in "change management," emphasizing the importance of baselining data and shadowing clinicians to ensure technology adapts to the human, not the other way around. Please note that the content here is for informational purposes only: should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security: and is not directed at any investors.

#6. Zach Rosen, Co-Founder of Brellium, securing clinical integrity through AI-powered compliance, regulatory crowdsourcing, and the "golden thread" of patient documentation.

Featuring: Zach RosenHosted by: James Chhetree This episode of Ainsley Health explores the critical intersection of clinical accuracy and patient safety with Zach Rosen, Co-Founder and CEO of Brellium. Hosted by James Chhetree, the conversation dives into how AI can serve as a definitive safety net for ambulatory care, ensuring that the "source of truth" in a medical chart remains both clinically valid and payer-compliant. Zach’s journey into health tech is deeply personal. After a core medical misdiagnosis led to years of health challenges for him and his family, he founded Brellium with a singular mission: to ensure that what happened to him never happens to another patient. By auditing millions of visits across all 50 states, Brellium aligns provider incentives with patient outcomes, moving beyond standard software into a realm where near-perfect accuracy is a requirement, not an option. As a second-time founder navigating the high-stakes world of medical regulation, Zach provides a masterclass on building trust in a noisy AI market: * The Regulatory Intelligence Network: How Brellium crowdsources "edge case" requirements from over 100 payers to provide real-time intelligence for independent and mom-and-pop practices. * The Golden Thread: Why the cohesion of the patient narrative—from initial visit to hospice care—is the ultimate defense against both federal oversight and adverse clinical outcomes. * Accuracy vs. Empathy: Zach’s counterintuitive stance that while accuracy is the bedrock of AI, empathy is the necessary bridge that ensures a patient actually internalizes and acts on clinical data. Brellium rejects the idea of "AI for the sake of AI." Instead, Zach emphasizes a customer-first philosophy where technology is merely the implementation detail for solving massive operational inefficiencies. He discusses: * Clawback Protection: The logic behind Brellium’s bold claim to foot the bill if a payer pulls back reimbursement on an approved chart—a move that perfectly aligns their success with their customers' risk mitigation. * The Ambulatory Focus: Why Brellium prioritizes the "mom-and-pop" businesses and few-site locations that render the vast majority of care in America but often lack access to enterprise-grade technology. * The Future of the Chart: Why humans will stop manually auditing PDFs, but the medical chart will remain the indispensable, verifiable source of truth for the patient journey. The episode concludes with Zach’s advice for technical founders: talk to a statistically significant number of people early on to compound your learnings. His most surprising insight? That early on, even the most serious documentation could be derailed by something as simple as a provider recording a therapy session spent playing Xbox—proving that without a safety net, even the most fundamental gaps can go unnoticed. Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors.

#5. Cole Johnson, Founder of Echo, pioneering social intelligence through AI-driven qualitative analysis at quantitative scale, democratic intent capture, and privacy-first monetization architecture.

Featuring: Cole Johnson Hosted by: Jay Gopal and James Chhetree This episode of Ainsley Health explores the future of social intelligence and the broken feedback loop between consumers and corporations with Cole Johnson, Founder of Echo. Hosted by Jay Gopal and James Chhetree, the conversation delves into how language models have unlocked an entirely new category of human understanding—one that treats every voice equally rather than amplifying the loudest. Cole's journey is a study in compounding curiosity. From founding La Tree (now Terra Nova) at Georgia Tech to prosthetics research and a Caltech fellowship, Cole discovered "shared autonomy"—the bidirectional negotiation between a human and an intelligent system. That insight became the intellectual foundation for Echo: language models could finally enable qualitative back-and-forth at a scale previously reserved only for quantitative systems. As a researcher-turned-founder at the intersection of AI and human behavior, Cole provides a rare perspective on why every existing method of understanding public intent is fundamentally flawed: The Broken Trifecta: Social listening captures only the loudest voices. Polling has a 0.1% completion rate. Focus groups max out at 50 people for massive cost. None can do qualitative analysis at quantitative scale. The Demographics Misconception: Demographics and psychographics were always just heuristics for intent—proxies mistaken for the real thing. Echo asks the right questions, to the right people, at the right time, achieving a nearly 90% completion rate. The Bot Problem: With 12 to 80 percent of voices on X potentially bots, Echo's platform fundamentally lacks the incentive structure that rewards bot behavior—no engagement to game, no audience to influence. Echo rejects the prevailing agentic AI philosophy of replacement. Rather than automating departments, Echo positions itself as a democratic listening device that routes genuine human feedback to the organizations that need it most. Cole discusses: Privacy by Architecture: Why separating the monetization vehicle from the communication medium is foundational for safe AI—drawing a direct line from advertising's degradation to the current danger of monetization bleeding into chat-based AI. Crisis Narrative Validation: How Echo's systems detect emerging narratives every five to ten minutes, then validate whether loud online voices actually represent majority sentiment through real user feedback. The Anti-Replacement Thesis: Instead of intermediating humans, Echo extracts, interprets, and routes insights to corporations that genuinely cannot hear what their consumers are saying. The episode concludes with Cole's five-year moonshot: a decentralized, white-label intelligence layer where bidirectional communication between organizations and individuals is routed at scale. His counterintuitive advice? In industry, try many things rapidly and backfill the foundation as weight accumulates. And his most surprising discovery? People use AI chatbots not as utilitarian tools, but as companions—replacing search engines with something far more conversational and revealing. Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors

#4. Martin Arum, CEO of FR Global Health & First Renaissance Ventures, accelerating biotech medical tourism, regenerative stem cell therapies, and AI-driven longevity.

Description Featuring: Martin Arum Hosted by: Jay Gopal and James Chhetree This episode of Ainsley Health explores the "Fountain of Youth" and the shifting healthcare business model with Martin Arum, Founder and CEO of FR Global Health. Hosted by Jay Gopal and James Chhetree, the conversation delves into how decentralized regulatory environments and cutting-edge biotech are converging to push the boundaries of human healthspan. Martin’s journey is a masterclass in professional evolution, transitioning from corporate law and defense technology into the high-stakes world of biotech and longevity. After building and selling a legal tech firm to a major government contractor, Martin redirected his focus toward healthcare, specifically cellular and neuro therapies. Today, he sits at the intersection of investment and innovation, identifying the "personality equation" that allows founders to survive the grueling emotional toll of the startup world. As a visionary in the longevity space, Martin provides a unique perspective on the "regulatory relief valve" found in cross-border medical hubs and how they are accelerating the path to a 150-year lifespan: * The Mexico Epiphany: Martin discusses the radical efficiency of the San Diego-Tijuana border, where "inaccessible" experimental therapies in the U.S. become immediate commercial realities. He explains how this "back door" to American healthcare is a multi-billion dollar industry driven by cost, access, and innovation. * The Investment Gap: With only 10% of FDA-track drugs reaching success, Martin highlights why traditional Venture Capital often retreats from early-stage biotech. He explores how family offices and foundations are stepping in to fund rare disease research and bridge the "binary risk" of long-term drug development. * Biological Rejuvenation: From 3D-printed body parts utilizing a patient’s own stem cells to AI-driven drug discovery, Martin outlines the shift from treating sickness to optimizing "healthspan"—ensuring our "active" years match our chronological longevity. FR Global Health is redefining the biotech roadmap by embracing a "dual-path" commercial model. By establishing R&D and clinical operations in more permissive regulatory environments like Mexico, they are able to iterate faster and provide life-changing therapies to patients today rather than a decade from now. Martin discusses: * AI as a Mega-Catalyst: Why the "AI Tsunami" is the ultimate accelerator for personalized medicine, diagnostics, and the design of complex medical devices. * Medical Tourism as a Systemic Shift: Moving beyond "cheap dental work" to specialized regenerative hubs that offer sophisticated neuromodulation and fertility treatments. * The Consolidation Curve: Why the current fragmentation of the longevity market will eventually give way to systemic, whole-body treatment models as the technology matures over the next 10 to 20 years. The episode concludes with a challenge to founders: the importance of self-discovery. Martin emphasizes that while technology like AI is a prerequisite for success, the "fabric" of the founder—their resilience and conviction—is the only thing that survives the "long haul" of biotech innovation. His bold advice? Pause and reflect on your own "personality equation" before trying to change the world’s biology. _______________________________________________________________ Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any Ainsley Capital fund. Ainsley Capital and its affiliates may maintain investments in the companies discussed.